Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (26)

I-32Christian Bartels

Getting a better description of treatment effects for time to event data using PKPD modelling

Wednesday 09:50-11:15

I-37Linnea Bergenholm

Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data

Wednesday 09:50-11:15

I-50Marion Bouillon-Pichault

Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma

Wednesday 09:50-11:15

I-63Blesson Chacko

Why patients may not benefit from effective oncology drugs

Wednesday 09:50-11:15

I-68Estelle Chasseloup

Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data

Wednesday 09:50-11:15

I-89Richard Dimelow

PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously

Wednesday 09:50-11:15

II-13Hyun A Lee

A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans

Wednesday 15:10-16:40

II-34Paolo Magni

Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics?

Wednesday 15:10-16:40

II-48Robin Michelet

A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance

Wednesday 15:10-16:40

II-59Bernard Ngara

A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents.

Wednesday 15:10-16:40

II-61Laura Zwep

Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data

Wednesday 15:10-16:40

II-87Javier Reig-López

Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software.

Wednesday 15:10-16:40

III-03François Riglet

Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM

Thursday 09:55-11:20

III-15Jérémy Seurat

Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage

Thursday 09:55-11:20

III-36Hadi Taghvafard

Modeling (a)symmetry of concentration-effect curves

Thursday 09:55-11:20

III-37Hiroyuki Takita

The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell

Thursday 09:55-11:20

III-40David Ternant

Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation

Thursday 09:55-11:20

III-45Carlos Traynor

Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival.

Thursday 09:55-11:20

III-70Sebastian Weber

Qualifying drug dosing regimens in pediatrics using Gaussian Processes

Thursday 09:55-11:20

III-72Gustaf Wellhagen

Modelling UACR as a clinical endpoint

Thursday 09:55-11:20

IV-04Ronan Duchesne

Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis

Thursday 15:25-16:50

IV-44Guenter Heimann

An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy.

Thursday 15:25-16:50

IV-60Itziar Irurzun-Arana

ACESO (A Cancer Evolution Simulation Optimizer)

Thursday 15:25-16:50

IV-64Jin Jin

Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling

Thursday 15:25-16:50

IV-72Vangelis Karalis

An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies

Thursday 15:25-16:50

IV-75Adrien Tessier

Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I – simulation study evaluating type I error and power of proof-of-concept trials

Thursday 15:25-16:50